Predict your next investment

Other

See what CB Insights has to offer

Investments

1

Portfolio Exits

1

About T-REGS

T-REGS Headquarter Location

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Latest T-REGS News

iOnctura Shows No Dose-limiting Toxicity and Reduced T-regs in Solid Tumor Study of PI3Kδ Inhibitor IOA-244 Presented at ESMO-IO

Dec 9, 2021

Geneva, SWITZERLAND GENEVA, Switzerland, Dec. 09, 2021 (GLOBE NEWSWIRE) -- iOnctura SA, a clinical stage oncology company targeting core resistance and relapse mechanisms at the tumor-stroma-immune interface, is presenting clinical data on its lead pipeline asset, the PI3Kδ inhibitor IOA-244, showing no dose-limiting toxicity and a reduction in T regulatory (Treg) cells. The data is being presented as a poster at the European Society of Medical Oncology’s Immuno-Oncology Congress (ESMO-IO) taking place on December 8–11, 2021 as a virtual meeting. The data demonstrates there were no dose-limiting toxicities in patients with solid tumors treated with IOA-244, including patients who were treated for up to 1 year duration. The PK profile of IOA-244 showed low inter- and intra-patient variability with no clinically relevant reactive metabolites detected. Mesothelioma, cutaneous and uveal melanoma – tumor types being treated with IOA-244 - are known to have a high burden of T regulatory cells. IOA-244 administration was associated with a reduction in Treg counts in the peripheral blood of patients with uveal melanoma, as measured using cytometry by time of flight (CyTOF). These data strengthen the rationale for treating patients with IOA-244 and expanding the DIONE-01 study, a two-part, first-in-human dose study evaluating IOA-244 in solid tumors and hematologic malignancies. The poster at ESMO-IO presents data from the first part (Part A) of the DIONE-01 study and is entitled “First-in-human (FIH), pharmacokinetic (PK) and pharmacodynamic (PD) study of IOA-244, a phosphoinositide 3-kinase delta (PI3Kδ) inhibitor, in patients with advanced metastatic mesothelioma, uveal and cutaneous melanoma” (P139). The e-poster presentation is available on the ESMO-IO virtual meeting platform and iOnctura’s website . IOA-244 is a novel phosphoinositide 3-kinase delta (PI3Kδ) inhibitor with an unprecedented preclinical and clinical profile, currently being investigated in Part B of the DIONE-01 trial. Contacts

T-REGS Investments

1 Investments

T-REGS has made 1 investments. Their latest investment was in Tech.eu as part of their Seed on April 4, 2014.

CBI Logo

T-REGS Investments Activity

investments chart

Date

Round

Company

Amount

New?

Co-Investors

Sources

4/23/2014

Seed

Tech.eu

$0.2M

Yes

1

Date

4/23/2014

Round

Seed

Company

Tech.eu

Amount

$0.2M

New?

Yes

Co-Investors

Sources

1

T-REGS Portfolio Exits

1 Portfolio Exit

T-REGS has 1 portfolio exit. Their latest portfolio exit was Tech.eu on October 07, 2021.

Date

Exit

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Acquirer

Sources

10/7/2021

Acquired

$99M

3

Date

10/7/2021

Exit

Acquired

Companies

Valuation

$99M

Acquirer

Sources

3

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.